Tumor regression induced by YM155, a novel, survivin suppressant, in human diffuse large B-cell lymphoma models

被引：0
|
作者：
Kaneko, Naoki [1 ]
Kita, Aya [1 ]
Nakahara, Takahito [1 ]
Nakata, Mari [1 ]
Koutoku, Hiroshi [1 ]
Sasamata, Masao [1 ]
机构：
[1] Astellas Pharma Inc, Appl Pharmacol Res Labs, Tsukuba, Ibaraki 3058585, Japan
来源：
JOURNAL OF PHARMACOLOGICAL SCIENCES | 2010年 / 112卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：260P / 260P
页数：1
相关论文
共 50 条
  • [1] A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma
    Cheson, Bruce D.
    Bartlett, Nancy L.
    Vose, Julie M.
    Lopez-Hernandez, Andres
    Seiz, Amanda L.
    Keating, Anne T.
    Shamsili, Setareh
    CANCER, 2012, 118 (12) : 3128 - 3134
  • [2] Tumor regression induced by YM155, a novel, small molecule survivin suppressant, in experimental human lung tumor models.
    Nakahara, Takahito
    Takeuchi, Masahiro
    Kinoyama, Isao
    Kita, Aya
    Yamanaka, Kentaro
    Matsuhisa, Akira
    Sasamata, Masao
    CANCER RESEARCH, 2006, 66 (08)
  • [3] Combination of YM155, a survivin suppressant with a STAT3 inhibitor: A new strategy to treat diffuse large B-cell lymphoma
    Kaneko, Naoki
    Kita, Aya
    Yamanaka, Kentaro
    Mori, Masamichi
    LEUKEMIA RESEARCH, 2013, 37 (09) : 1156 - 1161
  • [4] Combination of YM155, a Survivin Suppressant, with Bendamustine and Rituximab: A New Combination Therapy to Treat Relapsed/Refractory Diffuse Large B-cell Lymphoma
    Kaneko, Naoki
    Mitsuoka, Keisuke
    Amino, Nobuaki
    Yamanaka, Kentaro
    Kita, Aya
    Mori, Masamichi
    Miyoshi, Sosuke
    Kuromitsu, Sadao
    CLINICAL CANCER RESEARCH, 2014, 20 (07) : 1814 - 1822
  • [5] Safety and efficacy of YM155 in diffuse large B-cell lymphoma (DLBCL)
    Cheson, B. D.
    Vose, J. M.
    Bartlett, N. L.
    Lopez, A.
    Van der Jagt, R. H.
    Tolcher, A. W.
    Weisenburger, D. D.
    Seiz, A. L.
    Shamsili, S.
    Keating, A. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma (vol 118, pg 3128, 2012)
    Cheson, Bruce D.
    Bartlett, Nancy L.
    Vose, Julie M.
    Lopez-Hernandez, Andres
    Seiz, Amanda L.
    Keating, Anne T.
    Shamsili, Setareh
    Papadopoulos, Kyriakos P.
    CANCER, 2012, 118 (17) : 4365 - 4365
  • [7] YM155, a small molecule survivin suppressant, sensitizes human B-cell non-Hodgkin lymphoma to rituximab-induced apoptosis
    Kaneko, Naoki
    Kita, Aya
    Mori, Masamichi
    Sengoku, Takanori
    CANCER RESEARCH, 2012, 72
  • [8] YM155, a Novel Survivin Suppressant, Improves the Antitumor Effect of Rituximab and Rituximab-Containing Regimens in Diffuse Large B Cell Lymphoma (DLBCL) Xenograft Mouse Models
    Nakata, Mari
    Nakahara, Takahito
    Kita, Aya
    Mitsuoka, Keisuke
    Yamanaka, Kentaro
    Kaneko, Naoki
    Miyoshi, Sosuke
    Mori, Masamichi
    Koutoku, Hiroshi
    Sasamata, Masao
    BLOOD, 2009, 114 (22) : 1064 - 1064
  • [9] YM155, a novel survivin suppressant, induced downregulation of survivin and potent antitumor activities in experimental human prostate tumor xenograft models.
    Nakahara, T
    Takeuchi, M
    Isao, K
    Tsuyoshi, M
    Akira, M
    Kita, A
    Tominaga, F
    Yamanaka, K
    Sasamata, M
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9082S - 9083S
  • [10] Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma
    Kita, Aya
    Nakahara, Takahito
    Yamanaka, Kentaro
    Nakano, Kenji
    Nakata, Mari
    Mori, Masamichi
    Kaneko, Naoki
    Koutoku, Hiroshi
    Izumisawa, Nobuyuki
    Sasamata, Masao
    LEUKEMIA RESEARCH, 2011, 35 (06) : 787 - 792
12345